Metformin and Longevity: What the TAME Study Could Mean for Healthy Aging

For decades, metformin has been one of the most prescribed medications in the world for the treatment of type 2 diabetes. It is inexpensive, well-studied, and has an excellent long-term safety profile. But recently, metformin has gained attention for a different reason: its potential to slow the biological processes of aging.

This growing interest has led to one of the most anticipated clinical trials in longevity medicine—the Targeting Aging with Metformin (TAME) study.

While the final results are still pending, TAME represents a major shift in how medicine approaches aging. Instead of waiting for heart disease, dementia, or cancer to develop, researchers are asking a revolutionary question:

Can we delay multiple age-related diseases by targeting aging itself?

⸻

Why Was the TAME Study Created?

Modern medicine excels at treating individual diseases. We have medications for diabetes, high blood pressure, high cholesterol, osteoporosis, and many forms of cancer.

But aging is the greatest risk factor for nearly all of these conditions.

Researchers behind the TAME study believe that if we can slow the biological aging process, we may be able to delay the onset of multiple chronic diseases simultaneously—potentially extending healthspan, the years of life spent in good health, rather than simply increasing lifespan.

⸻

Why Metformin?

Metformin has been used safely for more than 60 years and has several characteristics that made it an attractive candidate for longevity research.

Studies suggest metformin may:

• Improve insulin sensitivity

• Reduce excessive glucose production by the liver

• Activate AMPK, often referred to as the body’s “metabolic master switch”

• Reduce chronic low-grade inflammation

• Improve mitochondrial efficiency

• Reduce oxidative stress

• Influence nutrient-sensing pathways involved in aging

In laboratory animals, metformin has shown modest lifespan extension in some models, although results have not been consistent across every species.

⸻

What Is the TAME Study?

TAME is designed to determine whether metformin can delay the development of multiple age-related diseases in older adults without diabetes.

Rather than measuring blood sugar alone, researchers are evaluating whether metformin delays the occurrence of:

• Heart attack and stroke

• Cancer

• Cognitive decline and dementia

• Physical disability

• Death from any cause

This represents a completely different way of thinking about medicine. Instead of treating disease after it appears, researchers hope to preserve health before disease develops.

⸻

Why Is TAME So Important?

If successful, TAME could help establish aging as a treatable biological process rather than an unavoidable consequence of getting older.

That would represent one of the largest paradigm shifts in modern medicine.

Although aging itself is not currently recognized as a disease, delaying biological aging could potentially reduce the risk of numerous chronic illnesses simultaneously.

⸻

What Do We Already Know?

Even before TAME, researchers noticed something interesting.

People with type 2 diabetes taking metformin often experienced health outcomes that were similar to—or in some studies better than—people without diabetes.

Observational studies have reported associations between metformin use and:

• Lower cardiovascular event rates

• Reduced all-cause mortality

• Lower incidence of certain cancers

• Better metabolic health

• Reduced inflammation

These findings are encouraging but do not prove that metformin causes these benefits. Observational studies can identify associations, but randomized clinical trials such as TAME are needed to establish cause and effect.

⸻

How Might Metformin Slow Aging?

Researchers believe metformin may influence several of the “hallmarks of aging.”

Improved Metabolic Health

As we age, insulin resistance becomes more common. Metformin improves insulin sensitivity and helps reduce excess glucose production, potentially lowering one driver of age-related disease.

AMPK Activation

AMPK is a cellular energy sensor that becomes active when energy availability is low.

Activation of AMPK encourages cells to:

• Produce energy more efficiently

• Repair cellular damage

• Reduce unnecessary growth signals

• Improve metabolic flexibility

Many scientists believe AMPK activation is one reason exercise produces broad health benefits.

Reduced Chronic Inflammation

Aging is associated with persistent low-grade inflammation, sometimes called “inflammaging.”

Metformin appears to reduce several inflammatory pathways, which may contribute to healthier aging.

Mitochondrial Function

Healthy mitochondria produce energy efficiently while limiting damaging reactive oxygen species.

Metformin may improve mitochondrial efficiency, although research in this area continues to evolve.

⸻

Does Everyone Need Metformin?

Not necessarily.

The potential benefits of metformin are likely greatest in individuals with:

• Prediabetes

• Insulin resistance

• Obesity

• Metabolic syndrome

For healthy, lean, physically active adults with excellent metabolic health, the magnitude of benefit is less certain.

Lifestyle interventions—including regular exercise, strength training, high-quality nutrition, adequate sleep, stress management, and maintaining a healthy body composition—remain the cornerstone of healthy aging.

⸻

Are There Risks?

Metformin is generally well tolerated, but like any medication, it carries potential risks.

Possible side effects include:

• Nausea

• Diarrhea

• Stomach discomfort

• Vitamin B12 deficiency with long-term use

Rare risk of lactic acidosis in people with significant kidney disease or certain serious medical conditions

Some studies have also suggested metformin may slightly reduce certain exercise-related adaptations, particularly in older adults performing resistance training. The clinical significance of this finding remains uncertain.

⸻

What About Low-Dose Metformin?

Some longevity-focused physicians prescribe lower doses—such as 250–500 mg of extended-release metformin nightly—to improve tolerability while exploring potential metabolic benefits.

However, the optimal dose for longevity has not been established, and metformin should not be viewed as a substitute for healthy lifestyle habits.

⸻

The Bottom Line

The TAME study represents one of the most exciting investigations in longevity medicine.

Rather than asking whether metformin lowers blood sugar, researchers are asking whether it can delay aging itself by preventing multiple chronic diseases.

While definitive results are still awaited, existing research suggests metformin influences many biological pathways involved in aging, including insulin signaling, inflammation, oxidative stress, mitochondrial function, and cellular energy regulation.

Whether these effects translate into meaningful improvements in healthspan for healthy adults remains one of the most important unanswered questions in preventive medicine.

At Morrell Wellness, we believe longevity medicine should always be personalized. Medications like metformin may play a role for selected patients, but they work best as part of a comprehensive strategy that includes nutrition, exercise, hormone optimization when appropriate, sleep, and individualized preventive care.

⸻

References

Barzilai N, et al. Metformin as a Tool to Target Aging. Cell Metabolism. 2016.

Justice JN, et al. Framework for the Targeting Aging with Metformin (TAME) Trial. Clinical Geriatric Medicine. 2020.

Campisi J, et al. From discoveries in ageing research to therapeutics for healthy ageing. Nature. 2019.

Kulkarni AS, et al. Geroscience-guided repurposing of FDA-approved drugs to target aging. Cell Metabolism.

American Diabetes Association. Standards of Care in Diabetes.